Glaxo Smith Kline, makers of the diabetes drug Avandia, narrowly escaped having their drug pulled from the market by FDA officials, if it weren’t for the greased palms. While one scientist appeared to be honest and try and tell the country that the drug is dangerous and that there are major heart risks, his voice was silenced by the droning hum of the Big Pharma money-making scheme engine once again (GSK’s reported net income was close to $15 billion in 2006).
